Feedback | Saturday, December 14, 2024

  • Twitter
  • Facebook
  • YouTube
  • Instagram

December 2, 2024 4:30 PM

4 oral GLP-1R obesity drugs in race for approval, Novo Nordisk leads: report

Four oral glucagon-like peptide-1 receptor (GLP-1R) drugs, currently under Phase III trials, are in the race for approval, according to a report. This follows the immense popularity of injectable GLP-1R drugs, such as Novo Nordisk’s Wegovy and Saxenda, Eli Lilly’s Zepbound, and Shanghai Benemae Pharmaceutical’s Yishengtai, all of which have been approved for obesity. The report by GlobalData, a data and analytics company, showed that 63 drugs are in active development, with four Phase II...

September 11, 2024 4:36 PM

Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial

Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects. The maker of blockbuster drugs Wegovy and Ozempic said in March that a Phase I trial of the pill version of amycretin showed participants lost up to 13.1% of their weight after 12 weeks, prompting shares to surge more than 8%. That compared to weight loss of about 6% after 12 weeks and 15% after 68 we...

July 11, 2024 7:32 PM

Pfizer moves forward with once-daily weight-loss pill

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice- daily version of the drug late last year. The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections. Some analysts expect the weight-loss drug market, currently dominated ...

July 9, 2024 4:57 PM

Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss

Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss. The analysis was published on Monday in JAMA Internal Medicine, a medical journal. It examined health records and other data to assess the pace and percentage of weight loss for overweight and obese people taking tirzepatide - the active ingredient in Lilly's Mounjaro a...

Visitors: 12985105
Last Updated: 14th Dec 2024